News | September 21, 2008

Early Aggressive Treatment Increases Survival for Many Brain Tumor Patients

September 22, 2008 - Early aggressive treatment with chemotherapy prior to radiotherapy may prolong survival for patients with anaplastic oligodendrogliomas according to new research from the Radiation Therapy Oncology Group (RTOG) presented at ASTRO 2008.

RTOG, an NCI-funded national clinical trials group, is a clinical research component of the American College of Radiology (ACR).

Longer-term results of an RTOG study show that administering chemotherapy prior to radiotherapy increased survival for oligodendroglioma patients. Progression-free survival also improved for those receiving the neoadjuvant chemotherapy, a benefit most evident in those whose tumors have deletions of chromosomes 1p and 19q.

“Our research, while providing some answers for patients with oligodendrogliomas, shows that longer follow-up and genetic profiles will be necessary to provide definitive answers for determining initial treatment strategies,” said Gregory Cairncross, M.D., of the University of Calgary Foothills Medical Centre in Calgary, Canada.

RTOG 9402, a phase III study, enrolled 299 anaplastic oligodendroglioma patients from July 1994 until March 2002 at 104 academic and community facilities in the U.S. and Canada. Patients were randomized to receive either standard radiotherapy alone or four cycles of neoadjuvant chemotherapy using procarbazine, lomustine, and vincristine followed by standard radiotherapy. The unadjusted estimated five-year overall survival rate for all patients entered on the study was slightly better for those who received neoadjuvant chemotherapy (49 vs. 46 percent). The adjusted five-year survival rate is significantly different favoring the experimental arm (hazard ratio = 0.66; 95 percent confidence interval (0.46, 0.95); p value = 0.02). For progression-free survival, the unadjusted estimated five-year rate for all patients entered on the study was significantly better for those who received neoadjuvant chemotherapy (37 vs. 22 percent; p value = 0.003). The adjusted five-year overall progression-free survival was also significantly different favoring the experimental arm (hazard ratio = 0.57; 95 percent confidence interval (0.41, 0.79); p value = 0.02).

Molecular analysis of oligodendrogliomas divides these tumors into two groups – those with deletion of both chromosomes 1p and 19q and those without. RTOG research has shown that patients with the deletions have a better response to treatment and overall survival. RTOG 9402 data reports that patients with the deletion had a median survival of 8.7 years vs. 2.7 years for those without the co-deletion (p

For more information: www.rtog.org, www.acr.org

Related Content

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI.

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI. Image courtesy of Exact Imaging

Feature | Prostate Cancer | January 20, 2021 | By Brian Wodlinger, Ph.D.
Historically when a patient had an elevated PSA (prostate specific antigen) test their urologist would take the next
The exceptionally high dose rate of the FLASH Beam is 3,000 times higher than normal therapy treatment (300 Gray per second vs. 0.1 Gray per second, Gray being a standard unit measuring absorbed radiation). Instead of treatment over 20 seconds, an entire treatment is completed in 6 milliseconds, giving the therapy its nickname, "FLASH." Image courtesy of Brian Pogue, PhD

The exceptionally high dose rate of the FLASH Beam is 3,000 times higher than normal therapy treatment (300 Gray per second vs. 0.1 Gray per second, Gray being a standard unit measuring absorbed radiation). Instead of treatment over 20 seconds, an entire treatment is completed in 6 milliseconds, giving the therapy its nickname, "FLASH." Image courtesy of Brian Pogue, PhD

News | Linear Accelerators | January 20, 2021
January 20, 2021 — A joint team of researchers from Radiation Oncology at Dartmouth's and...
Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type; PET Product" report has been added to ResearchAndMarkets.com's offering. The prostate cancer nuclear medicine diagnostics market in the US was valued at $194.47M in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach $431.76M by 2027.

Getty Images

News | Prostate Cancer | January 13, 2021
January 13, 2021 — The ...
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

News | Prostate Cancer | January 11, 2021
January 11, 2021 — A study
Mirion Technologies, Inc., a global provider of innovative radiation detection and measurement solutions, announced that it has acquired Sun Nuclear Corporation. Sun Nuclear is the global leader in radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world.
News | Quality Assurance (QA) | January 08, 2021
January 8, 2021 — Mirion Technologies, Inc., a global provider of
RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular healthcare solutions in 2021 with the introduction of a compact shielding facility designed to accommodate the latest models of low energy, self-shielded linear accelerators (linacs) that are now available worldwide. 

Image courtesy of Siemens Healthineers

News | Linear Accelerators | January 04, 2021
January 4, 2021 — RAD Technology Medical Systems (RAD) ann
RaySearch Laboratories AB has launched the latest release of its widely adopted treatment planning system. RayStation 10B adds support for brachytherapy planning and a new GPU Monte Carlo algorithm, which typically cuts final dose computation times to less than five seconds.
News | Brachytherapy Systems | December 29, 2020
December 29, 2020 — RaySearch Laboratories AB has launched the latest release of its widely adopted treatment plannin
According to recent studies, an increase in the COVID-19 positivity rate correlates to an increase in mortality from non-coronavirus-related diseases. This includes breast cancer, and researchers believe fear of contracting the virus compels patients to stay home instead of completing their post-lumpectomy radiotherapy regimens.

Image courtesy of Zeiss

News | Radiation Therapy | December 21, 2020
December 21, 2020 — According to recent studies, an increase in the...